The vaccine business is highly competitive. But Sanofi stands out particularly well. In this episode, Deborah Glasser, Sanofi’s Head of Vaccines for North America, delves into Sanofi's extensive history in the vaccine business, focusing on areas such as influenza, neurology, and rare diseases. Deborah provides a glimpse into the groundbreaking RSV monoclonal antibody, Beyfortus, designed to protect infants from the leading cause of hospitalizations. She emphasizes the unique approach of using a monoclonal antibody for newborns, highlighting its potential to revolutionize RSV prevention. Deborah also touches on Sanofi's efforts in flu prevention, such as consumer education and the importance of immunization, especially for the vulnerable population aged 65 and older. She sheds light on Sanofi's innovative use of Artificial Intelligence (AI) in both drug discovery and commercial practices and shares Sanofi's interest in collaborating with startups, particularly those aligned with he...